האם התאמת גובה ההשתתפות העצמית עבור תרופות לערך הטיפול יכולה להוות כלי לשיפור תוצאי הבריאות ובקרה על עלויות הטיפול הרפואי?

Translated title of the contribution: Can linking co-payment for drugs to evidence on treatment value improve health outcomes and contain healthcare costs?

Research output: Contribution to journalArticlepeer-review

Abstract

Co-payment strategies are frequently used by health insurers as a measure of containing healthcare costs. However, co-payments may reduce the use of essential drugs in chronically-ill patients. Recently, value-based insurance designs, where co-payments rates are determined by the value of the treatment, have been introduced in the United States. This review summarizes the results of recent studies in the United States, suggesting that reducing co-payments for highly valued treatments and raising co-payments for less effective treatments can lead to better compliance and better outcomes, with the potential of reducing long-term costs. Further research is needed to examine the feasibility of this approach and the long-term impact on quality of care and treatment costs in other healthcare systems, including Israel.
Translated title of the contributionCan linking co-payment for drugs to evidence on treatment value improve health outcomes and contain healthcare costs?
Original languageHebrew
Pages (from-to)524-528
Number of pages5
Journalהרפואה
Volume149
Issue number8
StatePublished - 1 Aug 2010

ASJC Scopus subject areas

  • Medicine (all)

Fingerprint

Dive into the research topics of 'Can linking co-payment for drugs to evidence on treatment value improve health outcomes and contain healthcare costs?'. Together they form a unique fingerprint.

Cite this